<?xml version="1.0" encoding="UTF-8"?>
<ref id="B55-pharmaceutics-13-00379">
 <label>55.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Scuteri</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Corasaniti</surname>
    <given-names>M.T.</given-names>
   </name>
   <name>
    <surname>Tonin</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Bagetta</surname>
    <given-names>G.</given-names>
   </name>
  </person-group>
  <article-title>Eptinezumab for the treatment of migraine</article-title>
  <source>Drugs Today</source>
  <year>2019</year>
  <volume>55</volume>
  <fpage>695</fpage>
  <lpage>703</lpage>
  <pub-id pub-id-type="doi">10.1358/dot.2019.55.11.3069864</pub-id>
  <?supplied-pmid 31840684?>
  <pub-id pub-id-type="pmid">31840684</pub-id>
 </element-citation>
</ref>
